Genome Canada well positioned for future growth as Meulien departs for top IMI job
This week marks the end of a key chapter in Canadian genomics research with the departure of Dr. Pierre Meulien. After five years as president and CEO of Genome Canada and three and a half years as chief scientific officer (CSO) of Genome British Columbia, Meulien is heading to Brussels to take the helm of the Innovative Medicines Initiative (IMI).
Other stories mentioning these organizations, people and topics
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 0 free articles remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.